Hantz Financial Services Inc. reduced its position in Novartis AG (NYSE:NVS – Free Report) by 5.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 65,220 shares of the company’s stock after selling 3,559 shares during the period. Hantz Financial Services Inc.’s holdings in Novartis were worth $9,298,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in NVS. Meramec Financial Planners LLC raised its position in shares of Novartis by 9.7% in the third quarter. Meramec Financial Planners LLC now owns 1,704 shares of the company’s stock valued at $243,000 after purchasing an additional 150 shares during the period. IFG Advisory LLC lifted its stake in shares of Novartis by 12.2% during the 3rd quarter. IFG Advisory LLC now owns 2,618 shares of the company’s stock valued at $373,000 after buying an additional 284 shares in the last quarter. AlTi Global Inc. lifted its stake in shares of Novartis by 240.7% during the 3rd quarter. AlTi Global Inc. now owns 11,174 shares of the company’s stock valued at $1,593,000 after buying an additional 7,894 shares in the last quarter. Diversified Trust Co boosted its holdings in Novartis by 2.1% in the 3rd quarter. Diversified Trust Co now owns 8,811 shares of the company’s stock worth $1,256,000 after buying an additional 185 shares during the period. Finally, Moors & Cabot Inc. boosted its holdings in Novartis by 1.9% in the 3rd quarter. Moors & Cabot Inc. now owns 29,315 shares of the company’s stock worth $4,179,000 after buying an additional 545 shares during the period. 13.12% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the stock. Sanford C. Bernstein reiterated a “neutral” rating on shares of Novartis in a research note on Wednesday, July 22nd. UBS Group reissued a “neutral” rating on shares of Novartis in a report on Wednesday, October 28th. JPMorgan Chase & Co. restated a “buy” rating on shares of Novartis in a research report on Sunday, August 9th. Berenberg Bank cut their price target on Novartis from $147.00 to $130.00 and set a “hold” rating for the company in a report on Friday, September 11th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $163.00 price target on shares of Novartis in a research report on Wednesday, October 28th. Six equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $152.25.
Get Our Latest Stock Analysis on Novartis
Novartis Stock Up 0.1%
NVS stock opened at $160.59 on Monday. The company has a quick ratio of 0.70, a current ratio of 0.88 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $306.42 billion, a PE ratio of 30.65, a PEG ratio of 2.94 and a beta of 0.40. Novartis AG has a twelve month low of $123.24 and a twelve month high of $170.46. The stock has a 50-day simple moving average of $149.13 and a two-hundred day simple moving average of $152.60.
Novartis (NYSE:NVS – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.25 by $0.21. Novartis had a return on equity of 41.04% and a net margin of 18.11%. The firm had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.53 billion. During the same period in the prior year, the business posted $2.25 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. On average, equities analysts predict that Novartis AG will post 9.10 EPS for the current fiscal year.
Novartis Profile
Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.
Featured Stories
- Five stocks we like better than Novartis
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
